$2.6 -0.2 -6.8%
Last Trade - 14/04/21
| Market Cap | £57.3m |
| Enterprise Value | £52.6m |
| Revenue | £452k |
| Position in Universe | 5341st / 6854 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.38 | 0.54 | 0.70 | 1.20 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Aptorum Group Limited is a pharmaceutical company dedicated to the discovery, development and commercializing of therapeutic assets to treat diseases, particularly infectious diseases and cancers (including orphan oncology indications). Through the establishment of drug discovery platforms, it enables the discovery of new therapeutics assets through systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. In addition to this, the Company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women’s health and other disease areas. It also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms.
| Last Annual | December 31st, 2019 |
| Last Interim | June 30th, 2020 |
| Public Since | December 18, 2018 |
| No. of Shareholders: | n/a |
| No. of Employees: | 36 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Market |
| Shares in Issue | 30,388,740 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 17 Hanover Square, LONDON, W1S 1BN, United Kingdom |
| Web | http://www.aptorumgroup.com/ |
| Phone | +44 20 80929299 |
| Contact | () |
| Auditors | Marcum Bernstein & Pinchuk LLP |
As of 14/04/21, shares in Aptorum are trading at $2.6, giving the company a market capitalisation of £57.3m. This share price information is delayed by 15 minutes.
Shares in Aptorum are currently trading at $2.6 and the price has moved by -28.57% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Aptorum price has moved by -52% over the past year.
Of the analysts with advisory recommendations for Aptorum, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Aptorum is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Aptorum is scheduled to issue upcoming financial results on the following dates:
Aptorum does not currently pay a dividend.
Aptorum does not currently pay a dividend.
Aptorum does not currently pay a dividend.
To buy shares in Aptorum you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Aptorum are currently trading at $2.6, giving the company a market capitalisation of £57.3m.
Here are the trading details for Aptorum:
Based on an overall assessment of its quality, value and momentum, Aptorum is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Aptorum are currently priced at $2.6. At that level they are trading at 0.4% discount to the analyst consensus target price of 0.00.
Analysts covering Aptorum currently have a consensus Earnings Per Share (EPS) forecast of -0.61 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aptorum. Over the past six months, the relative strength of its shares against the market has been -22.05%. At the current price of $2.6, shares in Aptorum are trading at -8.97% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Aptorum.
Aptorum's management team is headed by:
Here are the top five shareholders of Aptorum based on the size of their shareholding:
